国際学会発表
1. Nakagawa H, Groothuis DP,Blasberg RG: Effect of intracarotid hyperosmolar

infusion on brain tumor capillary permeability. The thirty-fifth anual meeting of theAmerican Academy of Neurology, San Diego, CA, USA, 1983,4.
2．Nakagawa H, Groothuis DP,Blasberg RG: Dexamethasone reduces brain tumor
extracellular space and capillary permeability. 36th Anual meeting of the American
Academy of Neurology, Boston, MA, April, 1984
3．Blasberg RG, Nakagawa H, Groothuis DP, Patlak CS: The extracellular space andspread of edema fluid in brain tissue adjacent to tumors is reduced by dexamethasone.
36th Anual meeting of the American Academy of Neurology,Boston, MA, April, 1984

4. Nakagawa H, Blasberg RG, Fenstermacher JD: Dexamethasone reduces brain tumor
extracellular space and capillary permeability and convective spread of edema fluid:
Implication for Diagnosis and Therapy. 6th International Symposium on Brain Edema,Tokyo, November 7-10,1984 (BEST '84)
5. Fenstermacher J,Yen M-H, Wright D, Nakagawa H, Blasberg R, and Patlak C: Effectsof Dexamethasone on local blood-brain transfer of AIB and RISA in traumatic cerebraledema. 6th International Symposium on Brain Edema, Tokyo,November 7-10,1984(BEST '84)
6. Wright DC, Yen MH, Nakagawa H, Blasberg RG, PatlakCS, Pettigrew KD,Fenstermacher J : Brain response to injury and dexamethasone: Reduction of
extracellular space and spread of edema fluid.

American Association of NeurologicalSurgeons (AANS), San Francisco, CA, April, 1984
7. Nakagawa H, Blasberg RG, Fenstermacher JD:Dexamethasone effect on[125I]albumin distribution in experimental RG-2 gliomas and Adjacent brain.The Sixth
International Symposium of Brain Edema,Tokyo, Nov.,1984.
8. RG Blasberg, H Nakagawa, MA Bourdon, DR Groothuis, CS Patlak, DD Bigner:
Regional localization of a glioma associated antigen defined by monoclonal antibody(Mab) 81C6. The thirth-sixth anual meeting of the American Academy of Neurology,
SanDiego, CA, USA, 1984,4.
9. H. Nakagawa, M. Yamada, K. Ikenaka:Basis for clinical intrathecal use of
5-fluoro-2'-deoxyuridine(FdUrd) in meningeal carcinomatosis. Sixth international
congress on anti-cancer treatment.1996, 2.6-9, Palais des Congres, Paris, France.
10. Nakagawa H, Yamada M, Iwatsuki K, Maeda N, Shimizu K, Ikenaka K:

Experimental study and clinical intrathecal use of 5-fluoro-2’-deoxyuridine (FDURD)
in the meningeal dissemination of malignant tumor.
Thirty-Third Annual Meeting of Ameican Society of Clinical Oncology (ASCO),
Colorado Convention Center, Denver, Colorado, May 17-20, 1997.
11.Nakagawa H, Tsuzuki T, Hirohashi M: Antitumor effects of BOF-A2 onexperimental glioma (203 glioma) and 5-fluorouracil distribution in subcutaneously andintracerebrally implanted 203 glioma and in ethylnitrosourea (ENU)-induced glioma.
American Association for Cancer Research (AACR) 89TH Annual meeting, March28-April 1, 1998.New Orleans, Louisiana. Abstract # 1527.
12.Nakagawa H, Maeda N, Tsuzuki T, Yamamoto H,Yamada M, Fukushima M,

Ikenaka K: Intracavitary chemotherapy with 5-fluoro-2’- deoxyuridine (FdUrd) in themalignant brain tumors. 34th Anual Meeting of Ameican Society of ClinicalOncology,

Los Angeles, CA,May, 1998
13. Nakagawa H: Combined chemotherapy with methotrexate (MTX) and6-thioguanine (6-TG) for the treatment of mouse meningeal carcinomatosis (MC)resistant to MTX. The 90th anual meeting of AACR, Philadelphia,PA, USA, April,
1999.
14.Nakagawa H, Isaka T, Miyahara E, Suzuki

T,Wada K, Kodama K, Hourai T:

Evaluation of intermittent chemotherapy with cddp after brain surgery in patients withmetastatic brain tumor from lung cancer .
36th

Anual

Meetingof

AmeicanSocietyofClinicalOncology,

New

Orleans,Louisiana, May, 2000.
15. Nakagawa H, Miyahara E, Wada K, Higashioka H, Tamura M: Surgical treatment ofmetastatic brain tumors from non-small cell lung cancer :Evaluation of postoperativeintermittent chemotherapy. The 12th world congress of neurosurgery, Sydney, Australia,September, 2001
16. Nakagawa H, Fukushima Y, Tamura M, Itoh K: Basis of intrathecal administrationof Y-27632, a specific ROCK inhibitor, in neoplastic meningitis. 94th Anual Meeting ofAmeican Society of Cancer Research, Washington DC, July, 2003.
17. Nakagawa H, Fukushima Y, Tamura M, Yoshioka K, Itoh K: Intrathecal or

intracavitary administration of sodium butyrate to treat neoplastic meningitis andmalignant glioma. 95th Anual Meeting of Ameican Society of Cancer Research,Orlando, USA, March, 2004

18. Nakagawa H, Tamura M, Fukushima Y,: Continuous intrathecal chemotherapy with
5-fluoro-2'-deoxyuridine (FdUrd) in treatment of leptomeningeal carcinomatosis.
40th Anual Meeting of Ameican Society of Clinical Oncologu, New Orleans, USA, June,
2004
19. Nakagawa H, Tamura M, Fukushima Y, Majima S,

Yoshioka K, Itoh K : Clinical

trial of continuous intrathecal or intracavitary infusionof sodium butyrate for

leptomeningeal carcinomatosis or recurrent malignant glioma. 96th Anual Meeting ofAmeican Society of Cancer Research, Anaheim,CA, USA, April 16-20, 2005
20. Nakagawa H, Yoshioka K, Itoh K : Intrathecal or intracavitaryadministration of sodium butyrate in patients with malignant glioma-Basic
research and Clinical trial. 17th International Congress on Anti-Cancer Treatment(ICACT), Paris, France, January 30~Feb.2, 2006.
21. Nakagawa H：Experimental study on the effect of intracarotid recombinant IL-2 onbrain capillary permeability of Gd-DTPA in ENU-induced rat glioma model-dynamic
study using animal MRI system- 97th Anual Meeting of Ameican Society of Cancer
Research, Washington DC, USA, April 1-5, 2006
22. H Nakagawa, M Yoshida, T Motozaki, K Yoshioka and K Itoh: Clinical results ofcontinuous intrathecal or intracavitary administration of sodium butyrate for patientswith recurrent and progressive malignant glioma. Experience with 23 cases 43rd Annual
Meeting of American Society of Clinical Oncology (ASCO), June 1-5, 2007,
MacCormic Place, Chicago, IL, USA
23. Hidemitsu Nakagawa: Symposium:Recent advance in metastatic brain tumor
therapy.; New Clinical Trials for Leptomeningeal Carcinomatosis. The International
Congress of Surgeons. 17th Joint Congress of Asia & Pacific Federations & 53rd Annual
Congress of the Japan Section, June 9~10, 2007., Kyoto, Japan
24. Nakagawa H, Kimura A, Yoshida M, Motozaki T, Yoshioka K, Itoh K.:
Evaluation of immunoreactivity of monocarboxylate transporter (MCT) 1 in recurrent
and progressive malignant glioma(MG): Speculation of the favorable factor inimmunoreactivity in the response to the continuous intrathecal infusion of sodium
butyrate (NaB). April 12-16, 2008,SanDiego, Ca
25. Nakagawa H, Yoshida M, Shindo M, Nishiyama H, Motozaki T, Yoshioka K, ItohK.:Correlation between immunoreactivity of monocarboxylate transporter 1 inmalignant glioma and tumor response to continuous intrathecal infusion of sodiumbutyrate , ECCO15-ESMO34, September 20-24, Berlin, Germany,2009
26. Nakagawa H, Yoshida M, Shindo M and Nishiyama H, Ri T and Motozaki T :Myelin basic protein in malignant brain tumour-source of increased myelin basic
protein in cerebrospinal fluid. EACR 21,Oslo, June 26-29, Norway, 2010
27. K. Itoh, K. Yoshioka, H. Nakagawa:Sodium butyrate inhibits glioblastoma in vasion
both in vitro and vivo. 50th Annual Meeting of the American Association for Cell
Biology. Philadelphia, PA, December 11~15, 2010
28. Nakagawa H, Yoshida M, Shindo M, Nishiyama H, Yamada M, Motozaki T 1), K
Yoshioka and K Itoh 2), Intrathecal Sodium Butyrate for Neoplastic Meningitis-Experimental Study and Clinical Trial Stockholm, Sweden, September 23~27, 2011.
29. Nakagawa H, Yoshida M, Shindo M, Nishiyama H, Ri T, Motozaki T, Tamura M
and Yamada M: Experimental trial of combined chemotherapy of intrathecal
methotrexate with oral 6-thioguanine in mouse meningeal carcinomatosis resistant tomethotrexate. EACR 22 - 22nd Biennial Congress of the European Association forCancer Research,07-10 July 2012, Barcelona, Spain
30. Hidemitsu Nakagawa, Kazuyuki Itoh: Sodium butyrate induced cellular senescenceand inhibited invasion of cancer cells with distinct mechanism. AACR2013, April 6-10,
Washington DC, USA
31. Hidemitsu Nakagawa, Masahiro Shindou, Satoru Sasagawa, Kazuyuki Itoh:
Sodium butyrate induced cellular senescence, inhibited invasion and modulated cellular
metabolism in glioblastoma cells. AACR2014, April 5-9, San Diego, USA